Butorphanol

CHEMBL33986 Phase 4 Aprovado Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

327.5 g/mol

LogP

3.8

Phase

4

A mixed opioid agonist-antagonist analgesic used for moderate-to-severe pain, including migraine headaches and labor pain. It activates kappa opioid receptors while acting as a partial antagonist at mu receptors, providing pain relief with a lower risk of physical dependence than pure mu agonists. It is available as a nasal spray and injectable solution.

Peso Molecular

327,5000 g/mol

LogP

3,80

TPSA

43,70 Å²

Regra dos 5 de Lipinski

Aprovado

Áreas Terapêuticas

Pain Management Generalized Anxiety Disorder Chronic Pain

Mecanismo de Ação

Binds to mu (μ), kappa (κ), and/or delta (δ) opioid receptors in the central and peripheral nervous system, mimicking endogenous endorphins. Activation of these G-protein-coupled receptors inhibits pain signal transmission and modulates the emotional response to pain.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mecanismo

Binds to mu (μ), kappa (κ), and/or delta (δ) opioid receptors in the central and peripheral nervous system, mimicking endogenous endorphins. Activation of these G-protein-coupled receptors inhibits pain signal transmission …

Estrutura 2D

SVG PNG

Cite this structure

Embed this structure

SMILES

Oc1ccc2c(c1)[C@@]13CCCC[C@@]1(O)[C@@H](C2)N(CC1CCC1)CC3

InChI

InChI=1S/C21H29NO2/c23-17-7-6-16-12-19-21(24)9-2-1-8-20(21,18(16)13-17)10-11-22(19)14-15-4-3-5-15/h6-7,13,15,19,23-24H,1-5,8-12,14H2/t19-,20+,21-/m1/s1

Molecular Formula

C21H29NO2

HBD / HBA

2 / 3

Ligações Rotacionáveis

2

Átomos Pesados

24

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Perguntas frequentes

A mixed opioid agonist-antagonist analgesic used for moderate-to-severe pain, including migraine headaches and labor pain. It activates kappa opioid receptors while acting as a partial antagonist at mu receptors, providing pain relief with a lower risk of physical dependence than pure mu agonists. It is available as a nasal spray and injectable solution.

Binds to mu (μ), kappa (κ), and/or delta (δ) opioid receptors in the central and peripheral nervous system, mimicking endogenous endorphins. Activation of these G-protein-coupled receptors inhibits pain signal transmission and modulates the emotional response to pain.

Yes, Butorphanol is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL33986. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 5361092. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

Procura informações acessíveis para o paciente?

Butorphanol no PillFYI

Estrutura

Dados Rápidos

Fórmula: C21H29NO2
Sinônimos: 5

Links Externos

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Aviso Médico

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.